O	0	1	[
O	1	6	Phase
O	7	8	Ⅲ
O	9	19	randomized
O	20	30	controlled
O	30	31	,
O	32	43	multicenter
O	43	44	,
O	45	56	prospective
O	57	62	study
O	63	65	of
B-intervention	66	77	recombinant
I-intervention	78	82	anti
I-intervention	82	83	-
I-intervention	83	87	HER2
I-intervention	88	97	humanized
I-intervention	98	108	monoclonal
I-intervention	109	117	antibody
I-intervention	118	119	(
I-intervention	119	128	Cipterbin
I-intervention	128	129	)
I-intervention	130	138	combined
I-intervention	139	143	with
I-intervention	144	155	vinorelbine
O	156	158	in
O	159	167	patients
O	168	172	with
O	173	177	HER2
O	178	186	positive
O	187	197	metastatic
O	198	204	breast
O	205	211	cancer
O	211	212	:
O	213	216	the
O	217	222	HOPES
O	223	228	Study
O	228	229	]
O	229	230	.

O	231	240	Objective
O	240	241	:
O	242	244	To
O	245	253	evaluate
O	254	257	the
O	258	266	clinical
O	267	275	efficacy
O	276	279	and
O	280	286	safety
O	287	289	of
O	290	301	recombinant
O	302	306	anti
O	306	307	-
O	307	311	HER2
O	312	321	humanized
O	322	332	monoclonal
O	333	341	antibody
O	342	343	(
O	343	352	Cipterbin
O	352	353	)
O	354	362	combined
O	363	367	with
O	368	379	vinorelbine
O	380	382	in
O	383	391	patients
O	392	396	with
O	397	401	HER2
O	402	410	positive
O	411	421	metastatic
O	422	428	breast
O	429	435	cancer
O	435	436	.

O	437	444	Methods
O	444	445	:
O	446	454	Patients
O	455	459	were
O	460	470	randomized
O	471	472	2
O	472	473	∶
O	473	474	1
O	475	477	to
O	478	482	test
O	483	488	group
O	489	492	and
B-control	493	500	control
I-control	501	506	group
O	506	507	.

O	508	516	Patients
O	517	519	in
O	520	524	test
O	525	530	group
O	531	539	received
O	540	549	Cipterbin
O	550	551	(
O	551	552	4
O	553	555	mg
O	555	556	/
O	556	558	kg
O	559	566	loading
O	567	571	dose
O	572	575	and
O	576	577	2
O	578	580	mg
O	580	581	/
O	581	583	kg
O	584	595	maintenance
O	596	600	dose
O	601	605	each
O	606	610	week
O	610	611	,
O	612	614	IV
O	614	615	)
O	616	624	combined
O	625	629	with
O	630	641	vinorelbine
O	642	643	(
O	643	645	25
O	646	648	mg
O	648	649	/
O	649	650	m
O	650	651	(
O	651	652	2
O	652	653	)
O	654	656	on
O	657	661	days
O	662	663	1
O	663	664	,
O	664	665	8
O	666	669	and
O	670	672	15
O	673	675	of
O	676	680	each
O	681	683	28
O	684	688	days
O	688	689	,
O	690	692	IV
O	692	693	)
O	693	694	.

O	695	703	Patients
O	704	706	in
O	707	714	control
O	715	720	group
O	721	729	received
O	730	741	vinorelbine
O	742	743	(
O	743	745	25
O	746	748	mg
O	748	749	/
O	749	750	m
O	750	751	(
O	751	752	2
O	752	753	)
O	754	756	on
O	757	761	days
O	762	763	1
O	763	764	,
O	764	765	8
O	766	769	and
O	770	772	15
O	773	775	of
O	776	780	each
O	781	783	28
O	784	788	days
O	788	789	,
O	790	792	IV
O	792	793	)
O	793	794	.

O	795	798	The
O	799	806	primary
O	807	810	end
O	811	816	point
O	817	820	was
B-outcome-Measure	821	832	progression
I-outcome-Measure	833	837	free
I-outcome-Measure	838	846	survival
I-outcome-Measure	847	848	(
I-outcome-Measure	848	851	PFS
I-outcome-Measure	851	852	)
O	852	853	.

O	854	861	Results
O	861	862	:
O	863	864	A
O	865	870	total
O	871	873	of
B-total-participants	874	877	315
O	878	886	patients
O	887	891	were
O	892	900	enrolled
O	901	905	from
O	906	909	Jan
O	910	914	2009
O	915	917	to
O	918	921	Jan
O	922	926	2013
O	927	928	(
B-intervention-participants	928	931	212
O	932	934	in
O	935	939	test
O	940	945	group
O	946	949	and
B-control-participants	950	953	103
O	954	956	in
O	957	964	control
O	965	970	group
O	970	971	)
O	971	972	.

O	973	976	The
B-outcome	977	983	median
I-outcome	984	987	PFS
O	988	990	of
O	991	995	test
O	996	1001	group
O	1002	1005	was
O	1006	1019	significantly
O	1020	1026	longer
O	1027	1031	than
O	1032	1036	that
O	1037	1039	of
O	1040	1047	control
O	1048	1053	group
O	1053	1054	,
B-iv-cont-median	1055	1057	39
I-iv-cont-median	1057	1058	.
I-iv-cont-median	1058	1059	1
I-iv-cont-median	1060	1065	weeks
O	1066	1068	vs
B-cv-cont-median	1069	1071	14
I-cv-cont-median	1071	1072	.
I-cv-cont-median	1072	1073	0
I-cv-cont-median	1074	1079	weeks
O	1080	1081	(
O	1081	1083	HR
O	1083	1084	=
O	1084	1085	0
O	1085	1086	.
O	1086	1088	24
O	1088	1089	;
O	1090	1092	95
O	1092	1093	%
O	1093	1095	CI
O	1095	1096	,
O	1097	1098	0
O	1098	1099	.
O	1099	1101	16
O	1101	1102	-
O	1102	1103	0
O	1103	1104	.
O	1104	1106	36
O	1106	1107	;
O	1108	1109	P
O	1109	1110	<
O	1110	1111	0
O	1111	1112	.
O	1112	1115	000
O	1116	1117	1
O	1117	1118	)
O	1118	1119	.

O	1120	1123	The
B-outcome	1124	1133	objective
I-outcome	1134	1142	response
I-outcome	1143	1147	rate
I-outcome	1148	1149	(
I-outcome	1149	1152	ORR
I-outcome	1152	1153	)
O	1154	1157	and
B-outcome	1158	1165	disease
I-outcome	1166	1173	control
I-outcome	1174	1178	rate
I-outcome	1179	1180	(
I-outcome	1180	1183	DCR
I-outcome	1183	1184	)
O	1185	1187	in
O	1188	1192	test
O	1193	1198	group
O	1199	1203	were
O	1204	1217	significantly
O	1218	1224	higher
O	1225	1229	than
O	1230	1235	those
O	1236	1238	in
O	1239	1246	control
O	1247	1252	group
O	1252	1253	,
B-outcome	1254	1257	ORR
O	1258	1261	was
B-iv-bin-percent	1262	1264	46
I-iv-bin-percent	1264	1265	.
I-iv-bin-percent	1265	1266	7
I-iv-bin-percent	1266	1267	%
O	1268	1270	vs
B-cv-bin-percent	1271	1273	18
I-cv-bin-percent	1273	1274	.
I-cv-bin-percent	1274	1276	45
I-cv-bin-percent	1276	1277	%
O	1278	1279	(
O	1279	1280	P
O	1280	1281	<
O	1281	1282	0
O	1282	1283	.
O	1283	1286	000
O	1287	1288	1
O	1288	1289	)
O	1290	1293	and
B-outcome	1294	1297	DCR
O	1298	1301	was
B-iv-bin-percent	1302	1304	79
I-iv-bin-percent	1304	1305	.
I-iv-bin-percent	1305	1307	72
I-iv-bin-percent	1307	1308	%
O	1309	1311	vs
B-cv-bin-percent	1312	1314	45
I-cv-bin-percent	1314	1315	.
I-cv-bin-percent	1315	1317	63
I-cv-bin-percent	1317	1318	%
O	1319	1320	(
O	1320	1321	P
O	1321	1322	<
O	1322	1323	0
O	1323	1324	.
O	1324	1327	000
O	1328	1329	1
O	1329	1330	)
O	1330	1331	.

O	1332	1335	The
B-outcome	1336	1345	incidence
I-outcome	1346	1348	of
I-outcome	1349	1360	neutropenia
O	1360	1361	,
B-outcome	1362	1372	leucopenia
O	1373	1376	and
B-outcome	1377	1393	erythrocytopenia
O	1394	1398	were
O	1399	1405	higher
O	1406	1408	in
O	1409	1413	both
O	1414	1420	groups
O	1420	1421	,
O	1422	1425	but
O	1426	1431	there
O	1432	1435	was
O	1436	1438	no
O	1439	1450	significant
O	1451	1461	difference
O	1462	1469	between
O	1470	1473	two
O	1474	1480	groups
O	1480	1481	.

O	1482	1485	The
O	1486	1490	most
O	1491	1497	common
O	1498	1505	adverse
O	1506	1512	events
O	1513	1523	associated
O	1524	1528	with
O	1529	1538	Cipterbin
O	1539	1543	were
B-outcome	1544	1552	infusion
I-outcome	1553	1562	reactions
O	1562	1563	.

B-outcome	1564	1568	Left
I-outcome	1569	1580	ventricular
I-outcome	1581	1589	ejection
I-outcome	1590	1598	fraction
O	1599	1606	reduced
O	1607	1609	to
O	1610	1614	less
O	1615	1619	than
O	1620	1622	50
O	1622	1623	%
O	1624	1626	in
O	1627	1628	5
O	1629	1637	patients
O	1637	1638	,
O	1639	1644	which
O	1645	1649	were
O	1650	1659	recovered
O	1659	1660	.

O	1661	1663	No
O	1664	1671	serious
B-outcome	1672	1686	cardiotoxicity
O	1686	1687	.

O	1688	1698	Conclusion
O	1698	1699	:
O	1700	1703	The
O	1704	1715	recombinant
O	1716	1720	anti
O	1720	1721	-
O	1721	1725	HER2
O	1726	1735	humanized
O	1736	1746	monoclonal
O	1747	1755	antibody
O	1756	1757	(
O	1757	1766	Cipterbin
O	1766	1767	)
O	1768	1776	combined
O	1777	1781	with
O	1782	1793	vinorelbine
O	1794	1797	has
O	1798	1809	significant
O	1810	1818	efficacy
O	1819	1822	and
O	1823	1827	good
O	1828	1834	safety
O	1834	1835	.

O	1836	1838	It
O	1839	1841	is
O	1842	1845	the
O	1846	1855	optimized
O	1856	1863	therapy
O	1864	1870	regime
O	1871	1874	for
O	1875	1883	patients
O	1884	1888	with
O	1889	1895	taxane
O	1895	1896	-
O	1896	1906	pretreated
O	1907	1911	HER2
O	1912	1920	positive
O	1921	1931	metastatic
O	1932	1938	breast
O	1939	1945	cancer
O	1945	1946	,
O	1947	1952	which
O	1953	1961	provides
O	1962	1966	more
O	1967	1975	targeted
O	1976	1983	therapy
O	1984	1997	opportunities
O	1998	2001	for
O	2002	2006	HER2
O	2007	2015	positive
O	2016	2022	breast
O	2023	2029	cancer
O	2030	2038	patients
O	2039	2041	in
O	2042	2047	China
O	2047	2048	.
